Pfizer Submits New Pediatric Data For Lipitor(R) (Atorvastatin) To The European Medicines Agency (EMEA)

Pfizer Inc (NYSE:PFE) announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission.

Go to Source

People who read this also read

• Pfizer Inc. Affirms Confidence In Its Hormone Therapy Medicines As Important Treatment Options
  In connection with the New York Times' recent coverage of hormone therapy1, Pfizer Inc. released important facts and context to respond to the newspaper's account. Pfizer believes the coverage is based on a misleading and selective reading of both the science and history of hormone therapy (HT) medi...
• ChemGenex’s Marketing Authorization Application For Omacetaxine Mepesuccinate Validated By The European Medicines Agency
  ChemGenex Pharmaceuticals Limited (ASX:CXS) announced that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and...
• How to Reduce & Relieve Headaches : Relieving Headache Tips
  Get a summary regarding headaches, symptoms and treatments as well as resources for further information with expert medical tips in this free online headache relief video clip. Expert: Dr. Susan Jewell Bio: Dr. Susan Jewell is a British born educated bilingual Asian with a British accent and can...
• Complementary and Alternative Medicines
  These systems are commonly based on belief as opposed to science. In some cases alternative practices are adopted by conventional systems and therefore lose their “alternative” classification. However, these alternatives are generally used in place of conventional methods. Alternative medicin...
• Forty Years’ War: Medicines to Deter Some Cancers Are Not Taken
  As the war on cancer continues, with little change in the mortality rate, the few drugs proved to deter cancer are widely ignored, researchers say. (Source: NYT > Health) Go to Source...